BrainsWay is a commercial stage medical device company. Co. is engaged in developing and providing technological solutions for the treatment of a variety of brain disorders. Co.'s flagship technology is based on Deep Transcranial Magnetic Stimulation (TMS). Co.'s treatment is FDA cleared for treating depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatments. Co. maintains clinical research programs with scientists worldwide, collaborating with institutions and researchers in clinical trials covering various neuropsychiatric and neuroscience applications. The BWAY stock yearly return is shown above.
The yearly return on the BWAY stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BWAY annual return calculation with any dividends reinvested as applicable (on ex-dates).
|